emporia: Smartphones Now More Popular Than Landline Phones Among the Over 60s
4.9.2019 10:00:00 EEST | Business Wire | Press release
Three out of four senior citizens would rather live without a conventional landline telephone than their smartphone. These are the findings of the 2019 Senior Citizens Survey: Smart Technology - Everyday, conducted by emporia Telecom in partnership with the German Senior Citizens League, in which 500 smartphone owners aged over 60 were interviewed.
Digital communication has become a simple matter of fact for many older people . One significant reason according to 83 percent of interviewees is: it is easier to maintain contact with family and friends via a smartphone.
According to the survey, three-quarters of senior citizens don’t want to be without their smartphone when they are out and about. It's also essential to them when travelling. It means that they always have useful information to hand, like weather forecasts and maps.
But it's far from every senior citizen that enjoys the benefits of the digital world. “75 million senior citizens in the EU today still don't own a smartphone. Yet there is an ever-increasing number of day-to-day activities that can only be performed with one. It's important to keep up to pace with modern communication technology so that you don’t suddenly find yourself cut adrift,” says Eveline Pupeter, owner and CEO of emporia Telecom. “It's our mission to guide older people into the digital future.”
The survey clearly identifies the concerns and difficulties experienced by senior citizens. Many older people worry about being left behind in a technology-driven world. For example, they wonder if they will even be able to perform daily errands and tasks such as using banking services, dealing with public authorities or buying bus and train tickets just as easily as they could before. “There's no stopping the progress of technology, but technology can also be simplified,” says emporia boss Eveline Pupeter. “We are seeking to gradually break down the fear of interacting with technology, and to help get the older generation up and ready for the future with user-friendly smartphones.
emporia is presenting two innovations simultaneously this September: The emporiaSMART.3 and the emporiaSMART.3mini. Despite their simplicity of use, both smartphones are fully intelligent, highly complex and state-of-the-art devices.
The emporiaSMART.3 is an easy-to-use top-class smartphone equipped with all the usual features such as two cameras, a powerful battery, Wi-Fi, Bluetooth, GPS, 5.5” screen, Type-C charging etc. It has a simple interface and mechanical home button and it’s also dust and splash-proof, compatible with hearing aids, has a sound amplifier, emergency call button, charging station and learning manual.
The SMART.3mini is something special. It was developed specially for men who wanted a compact smartphone that would easily fit into their trouser or shirt pocket. The SMART.3mini features a 4.95 inch touchscreen, meaning it's still easy to see and use. Spec-wise he mini is every bit the equal of its big brother, the SMART.
Talking about her mission, Eveline Pupeter says: “75 million of 65+ senior citizens in the EU still don't have a smartphone. It's emporia's goal to guide this generation into the digital future. Because being “smart” has nothing to do with age.”
The Linz-based manufacturer has a dual approach towards bringing digitalisation to the older generation. Its hardware and software solutions are precisely tailored for this target group. But it has also developed new training courses (such as Smartphones for Beginners, WhatsApp courses, Staying Secure on the Smartphone) to make it easier for senior citizens to get started.
emporia, the technology leader
emporia is an Austrian company that develops, manufactures and markets mobile telephones, smartphones and apps for the older generation. emporia’s products also include a wide range of accessories and landline telephones. Founded in 1991, emporia now operates in more than 30 countries around the world. The company is wholly owned by Eveline Pupeter who runs the business, together with her experienced management team. emporia employs 100 people. Its head office is located in the city of Linz on the banks of the Danube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005082/en/
Contact information
Walter Deil
+43 670 7010 322
deil@emporia.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
